8-K: Disc Medicine's Bitopertin Faces FDA Setback

Disc Medicine received a Complete Response Letter from the FDA for its bitopertin New Drug Application, requiring additional clinical data from the ongoing APOLLO study.

Summary

• Disc Medicine, Inc. received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on February 13, 2026, regarding its New Drug Application (NDA) for bitopertin as a treatment for erythropoietic protoporphyria (EPP).
• The FDA's primary objection concerned the sufficiency of protoporphyrin IX (PPIX) as a surrogate biomarker, requesting the outcome of the ongoing APOLLO study before making a decision.
• While previous trials (AURORA and BEACON) showed significant PPIX reduction, the FDA concluded they did not demonstrate a clear association between PPIX change and sunlight exposure-based endpoints.
• Disc Medicine is committed to completing the APOLLO study by Q4 2026 and plans to use its results to resubmit the NDA.
• The company expects to request a Type A meeting with the FDA to discuss its resubmission approach.
• A potential updated FDA decision is anticipated by mid-2027, following a typical 6-month review period for CRL responses.
• Disc Medicine is well-capitalized, maintaining cash runway guidance into 2029, covering the APOLLO readout and other pipeline milestones.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a significant setback due to the FDA's CRL, which delays bitopertin's potential approval and requires further clinical data. While the company has a clear path forward with the APOLLO trial and strong cash position, the regulatory hurdle introduces uncertainty and extends the timeline to market.

Positives

• Disc Medicine is well-capitalized, with a cash runway extending into 2029, covering the APOLLO readout and additional key pipeline milestones.
• The APOLLO trial enrollment is expected to complete in March 2026, several months ahead of previous guidance.
• The FDA expressed willingness to discuss options to meet requirements, including the submission of results from the ongoing APOLLO trial, indicating a clear path forward.
• The company remains committed to advancing bitopertin for EPP and believes in its potential as a disease-modifying therapy.
• Current clinical trial participants will continue to have access to bitopertin.

Negatives

• The FDA issued a Complete Response Letter (CRL) for bitopertin's New Drug Application (NDA) for erythropoietic protoporphyria (EPP).
• The FDA's main objection was the insufficiency of protoporphyrin IX (PPIX) as a surrogate biomarker, requiring additional clinical endpoint data.
• The CRL delays the potential approval of bitopertin, pushing a possible FDA decision to mid-2027.
• The FDA concluded that prior trials (AURORA and BEACON) did not show sufficient evidence of association between PPIX change and sunlight exposure-based endpoints.

Risks

• The adequacy of Disc Medicine's capital to support its future operations and successfully initiate and complete clinical trials.
• Difficulty in predicting the time and cost of developing product candidates.
• The timing of initiation of planned preclinical studies and clinical trials.
• The timing of the availability of data from clinical trials.
• The risk that results of preclinical studies and clinical trials may not be predictive of future results or support further development and marketing approval.
• The content and timing of decisions made by the FDA and other regulatory authorities.
• The company's ability to identify additional product candidates with significant commercial potential and expand its pipeline.

Future Outlook

Disc Medicine plans to respond to the FDA's Complete Response Letter by submitting data from the ongoing APOLLO trial, with topline data expected in Q4 2026. The company anticipates requesting a Type A meeting with the FDA to discuss its resubmission strategy. Following the resubmission, an updated FDA decision on bitopertin for EPP is potentially expected by mid-2027. The company also has several other pipeline milestones planned for DISC-0974 and DISC-3405, with Phase 2 data readouts and Phase 3 initiations expected in 2026 and 2027.

Management Comments

• "Disc is committed to delivering bitopertin to patients and will focus on diligently completing the APOLLO study by Q4 2026 and responding to the FDA CRL."
• "Disc's belief in the importance of bringing a potential disease modifying therapy to the EPP community and the potential for bitopertin to set a new standard of care in EPP has not changed."
• "Disc has made every effort to bring bitopertin to the EPP community more quickly; while these efforts have not come to fruition, we remain committed to advancing the program and pursuing FDA approval of bitopertin."
• "During this process, Disc is committed to providing continued access to bitopertin for current clinical trial participants."

Industry Context

StockSavvy.ai notes that the FDA's issuance of a Complete Response Letter for bitopertin highlights the increasing scrutiny on surrogate endpoints, particularly in accelerated approval pathways for rare diseases. While PPIX reduction has strong mechanistic plausibility for EPP, the FDA's demand for direct clinical endpoint correlation underscores a broader trend towards more robust evidence of patient benefit. This situation is not uncommon in drug development, especially for novel therapies in niche indications, and often requires additional, well-powered studies to satisfy regulatory bodies.

Stakeholder Impact

• Shareholders: Potential negative impact due to delayed approval and increased uncertainty, possibly leading to share price volatility.
• EPP Patients: Delayed access to a potentially disease-modifying therapy, though current clinical trial participants will maintain access.
• Employees: Continued focus on completing the APOLLO trial and advancing the pipeline.
• Regulatory Authorities: The FDA's decision reinforces its commitment to rigorous evidence for drug efficacy, even for rare diseases.

Next Steps

• Request a Type A meeting with the FDA to review the approach for resubmission.
• Complete enrollment in the APOLLO trial by March 2026.
• Present topline data from the APOLLO trial in Q4 2026.
• Submit a response to the CRL in late 2026, utilizing the APOLLO trial data.
• Anticipate an updated FDA decision by mid-2027.
• Initiate Ex-US regulatory submissions for bitopertin.
• Topline RALLY-MF Phase 2 data for DISC-0974 (Anemia of Myelofibrosis) in 2H 2026.
• End of Phase 2 Meeting and Phase 3 initiation for DISC-0974 (Anemia of Myelofibrosis) in 2027.
• RALLY-IBD Phase 2 initiation for DISC-0974 (Anemia of Inflammatory Bowel Disease) in 1H 2026.
• RALLY-IBD Phase 2 Data for DISC-0974 (Anemia of Inflammatory Bowel Disease) in 2H 2026/2027.
• Initial RESTORE-PV Phase 2 Data for DISC-3405 (Polycythemia Vera) in 1H 2026.
• Topline RESTORE-PV Phase 2 Data, End of Phase 2 Meeting, and Phase 3 initiation for DISC-3405 (Polycythemia Vera) in 2H 2026/2027.
• Initial Phase 1b Data for DISC-3405 (Sickle Cell Disease) in 1H 2026.
• Topline Phase 1b data and Phase 2 initiation for DISC-3405 (Sickle Cell Disease) in 2H 2026/2027.

Key Dates

Recommendation

The FDA's Complete Response Letter for bitopertin is a significant setback, delaying market entry and introducing regulatory uncertainty. However, the company has a clear path forward with the APOLLO trial, a strong cash position extending into 2029, and a diversified pipeline. While the immediate news is negative, the long-term potential remains, warranting a "hold" recommendation as investors await the APOLLO trial results and subsequent FDA decision.

Keywords

Disc Medicine, Bitopertin, FDA, Complete Response Letter, Erythropoietic Protoporphyria, EPP, New Drug Application, NDA, APOLLO trial, Clinical trial, Biomarker, Protoporphyrin IX, Rare disease, Biotechnology, Pharmaceutical, Drug development